{
    "medicine_id": "f8890327ae64c6f2dc816eb35491a243cbbbd330",
    "platform_id": "DB13997",
    "metadata": {
        "name": "Xofluza 20 mg 1 Tablet film coated",
        "composition": "20 mg 1 Baloxavir marboxil",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of influenza A and B virus infection L1473 L1475 FDA label in patients 12 and older who have been symptomatic for no more than 48 hours Clinical trials of this drug did not include subjects 65 years of age and older to determine whether they respond in a different way than younger subjects FDA label",
            "contraindications": {
                "disease": "Ld50 oral rats 2000 mg kg MSDS Pregnancy Risk There are no available data on the use of this drug in pregnant women to predict or inform a drug associated risk of adverse developmental outcomes However there are known risks to the mother and fetus associated with influenza virus infection during pregnancy In animal reproduction studies no adverse developmental effects were observed in rats or rabbits with oral administration of Baloxavir marboxil at exposures approximately 5 rats and 7 rabbits times the systemic Baloxavir exposure at the maximum recommended human dose FDA label The estimated background risk of major birth defects and miscarriage for the indicated population is not known at this time FDA label Breastfeeding There are no data on the presence of this drug in human breastmilk the effects on the breastfed infant or the effects on milk production Baloxavir and its related metabolites were present in the milk of lactating rats FDA label Carcinogenicity Carcinogenicity studies have not been completed with baloxavir marboxil FDA label Mutagenesis Baloxavir marboxil and the active metabolite baloxavir were not shown to be mutagenic in in vitro and in in vivo genotoxicity assays which included bacterial mutation assays in S typhimurium and E coli micronucleus tests with cultured mammalian cells and in the rodent micronucleus assay FDA label Impairment of Fertility In a fertility and early embryonic development study in rats doses of baloxavir marboxil at 20 200 or 1 000 mg kg day were given to female animals for 2 weeks before mating during mating and until day 7 of pregnancy Male animals were dosed for 4 weeks before mating and throughout mating There were no measured effects on fertility mating performance or early embryonic development at any dose level resulting in systemic drug exposure AUC approximately 5 times the MRHD maximum recommended human dose FDA label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Baloxavir marboxil is a selective inhibitor of influenza cap dependent endonuclease which prevents polymerase function and therefore influenza virus mRNA replication L1475 A39907 It has shown therapeutic activity against influenza A and B virus infections including strains resistant to current antiviral agents A39894 This drug inhibits an enzyme required for viral replication thus rapidly treating flu virus infection L1475 FDA label and alleviating the symptoms associated with infection A single dose of this agent was shown to be superior to placebo in relieving influenza symptoms and superior to both oseltamivir and placebo drug in virologic outcomes marked by decreased viral load A39894 The safety profile of Baloxavir marboxil compared favorably with that of oseltamivir making it an effective treatment option for treatment of the flu virus in one single dose L1475 A39894",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB10317",
                        "description": "The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB10343",
                        "description": "The therapeutic efficacy of Bacillus calmette guerin substrain tice live antigen can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB10804",
                        "description": "The therapeutic efficacy of Bacillus calmette guerin substrain connaught live antigen can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB10805",
                        "description": "The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB11003",
                        "description": "The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB11050",
                        "description": "The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB12386",
                        "description": "The therapeutic efficacy of Bacillus calmette guerin substrain danish 1331 live antigen can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB12768",
                        "description": "The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB14409",
                        "description": "The therapeutic efficacy of Human adenovirus e serotype 4 strain cl 68578 antigen can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB14443",
                        "description": "The therapeutic efficacy of Vibrio cholerae CVD 103 HgR strain live antigen can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB14685",
                        "description": "The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB10318",
                        "description": "The therapeutic efficacy of Varicella Zoster Vaccine Live attenuated can be decreased when used in combination with Baloxavir marboxil"
                    },
                    {
                        "drugbank-id": "DB01241",
                        "description": "The metabolism of Baloxavir marboxil can be decreased when combined with Gemfibrozil"
                    },
                    {
                        "drugbank-id": "DB01544",
                        "description": "The metabolism of Baloxavir marboxil can be decreased when combined with Flunitrazepam"
                    },
                    {
                        "drugbank-id": "DB01609",
                        "description": "The metabolism of Baloxavir marboxil can be decreased when combined with Deferasirox"
                    },
                    {
                        "drugbank-id": "DB05928",
                        "description": "The metabolism of Baloxavir marboxil can be decreased when combined with Dovitinib"
                    },
                    {
                        "drugbank-id": "DB06210",
                        "description": "The metabolism of Baloxavir marboxil can be decreased when combined with Eltrombopag"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}